Vaxart, Inc. (VXRT)

Vaxart, Inc. is a biotechnology company that focuses on developing oral vaccines administered by tablet rather than by injection. Founded in 2004 by Sean Tucker, the company is headquartered in South San Francisco, California. Vaxart is particularly known for its innovative approach to vaccine delivery, which aims to make immunizations more accessible, particularly in regions with limited medical infrastructure. The company gained attention during the COVID-19 pandemic with its oral COVID-19 vaccine candidate. Utilizing proprietary vector technology, Vaxart believes its oral vaccines can improve distribution efficiencies and patient compliance, while potentially reducing the cost of vaccine administration. Vaxart is publicly traded on the NASDAQ under the ticker symbol VXRT. Though early in commercialization and revenue generation, its groundbreaking work in the vaccine field has positioned the company as a significant player to watch in biotech innovation. With a continual focus on infectious diseases, Vaxart's mission is to improve global health through easier vaccine delivery.